Pfizer Inc. Stock
Price
Target price
€49.08
€49.08
2.090%
1.0
2.090%
?
08.12.22 / Tradegate
WKN: 852009 / Symbol: PFE / Name: Pfizer / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pfizer Inc. Stock
There is an upward development for Pfizer Inc. compared to yesterday, with an increase of €1.00 (2.090%).
Currently there is a rather positive sentiment for Pfizer Inc. with 9 Buy predictions and 4 Sell predictions.
With a target price of €55.00 there is a slightly positive potential of 12.062% for Pfizer Inc. compared to the current price of €49.08.
Our community identified positive and negative aspects for Pfizer Inc. stock for the coming years. 14 users see the criterium "Worthwhile Investment for the next years" as a plus for the Pfizer Inc. stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.
Pros and Cons of Pfizer Inc. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 2.090% | 1.029% | 4.337% | 8.344% | -3.670% | 49.079% | 70.446% |
| Merck & Co. Inc. | 0.190% | 0.766% | 4.158% | 63.101% | 54.569% | 30.846% | 123.260% |
| Eli Lilly Corp. | -1.190% | 0.028% | -3.296% | 63.615% | 42.782% | 225.596% | 380.355% |
| AbbVie Inc. | -0.230% | 2.383% | 6.589% | 46.406% | 32.090% | 99.543% | 92.743% |
Comments
News
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV)
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease
Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the
